Business Model Breakdown
How Sarepta Therapeutics Inc Makes Money
SRPT
Market Cap
$2.3B
Annual Revenue
$2.4B
Profit Margin
-38.3%
Employees
1,372
The Short Version
Sarepta Therapeutics is a specialized biopharmaceutical company that focuses on developing and selling innovative gene and RNA-based treatments for devastating rare genetic diseases, primarily Duchenne muscular dystrophy (DMD). They make money by discovering new therapeutic candidates, rigorously testing them in clinical trials, securing regulatory approvals, and then selling these high-cost, specialized medications directly to patients through healthcare systems. Their goal is to provide life-changing treatments for conditions with limited options, relying on the success of their product launches and market penetration within these niche patient populations.
Where the Revenue Comes From
Product sales of gene therapies (e.g., Elevidys) (~50-60% of revenue)
Product sales of PMO (phosphorodiamidate morpholino oligomer) drugs (e.g., Exondys 51, Vyondys 53, Amondys 45) (~40-50% of revenue)
Who buys: Patients diagnosed with rare genetic diseases (primarily DMD), their prescribing physicians, and hospital/infusion centers.
Why It Works (Competitive Advantages)
- ✔First-mover advantage and early approvals in DMD gene therapy (Elevidys)
- ✔Proprietary RNA-based therapeutic platforms and extensive rare disease pipeline
- ✔Established regulatory experience with multiple approved DMD products
Economic Moat: Narrow (Intangible Assets/IP (patents for gene and RNA therapies), Switching Costs (patients on successful, complex rare disease treatments are unlikely to switch))
What Our Analysis Says
DVR Score as of April 5, 2026
Sarepta's 10x growth potential remains highly challenged by persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance ($1.2B-$1.4B from $1.86B in 2025). While recent initial Phase 1/2 siRNA data shows promise for future pipeline diversification and an sNDA for traditional approval of existing PMOs is planned, these bright spots are overshadowed by current operational struggles. Analyst sentiment is largely negative, with price targets well below the current stock price. The company maintains a first-mover advantage in DMD gene therapy, but significant improvements in commercialization and consistent pipeline execution are critical for any substantial re-rating.